A venture capital firm that looks for and invests in talented entrepreneurs pushing humanity forward with innovation, providing capital, mentorship, and access to global connections.

Pier 70 Ventures

At Pier 70, we invest in impact-driven innovation. We find and fund disruptive technologies with the potential to shake up the status quo in healthcare. Entrepreneurs choose Pier 70 for capital and counsel, and we help them build diverse teams well-positioned to achieve financial success. Our success will be measured by their success and the collective value that we create.

Pier 70 Ventures advisor, Dennis Liotta, brilliant innovator, humanitarian and visionary leader in the field of drug discovery keynotes this fall.

Pier 70 Ventures portco, Acclinate receives the Blue Knight award from Johnson & Johnson and Biomedical Advanced Research and Development Authority (BARDA). Congratulations to Del Smith, PhD, Tiffany Whitlow and the Team.

https://lnkd.in/gRg5D45R

Pier 70 Ventures Managing Partner, R. Miller Adams delivers the keynote at Venture Mechanics Startup Incubator / Accelerator event, Black in Tech Venture Conference.   Keynote will be followed by a panel with Aina A., Madin Akpo-Esambe, Sarah Studer, and moderated by Evan Poncelet.

Pier 70 celebrates the continued success of our portfolio company, Acclinate, and the team’s successful completion of a $7 million Series A round. “This is an important mile marker in their journey to success, because it validates their thesis, their vision and most of all, their ability to execute flawlessly as a team. Del and Tiffany have maintained a culture of camaraderie and excellence in a growing team, while establishing themselves in a nascent market and are now regarded as the leaders in bringing equity to clinical trials." Says Preetha Ram, Managing Partner.

Shaun Hawkins, Managing Partner adds, “Establishing trust with large pharmaceutical companies is an art and a science, particularly when it relates to clinical trials. Acclinate’s attention to customer and community needs along with the manner in which they execute have led multiple partnerships with Big Pharma. We look forward to participating in Acclinate’s continued growth. We’re confident that the addition of strategic investors, Cencora and Labcorp will serve to accelerate that growth.”  
https://lnkd.in/gGGjiHrt
#healthequity #venturecapital #futureofhealth #diversityiclinicaltrials #aiforhealth

Good way to start the weekend by celebrating with the Acclinate team and my colleague and co-lead, Shaun Hawkins, as founders, Del and Tiffany close their next round.  Bringing diversity to clinical trials is tough, but they are leading the way!

Managing Partner Preetha Ram to moderate a panel on AI in Healthcare at #tiecon2024! If you are attending the conference, we'd love for you to meet her.
R. Miller Adams Shaun Hawkins Robert (Bob) Balk Minnie Sarwal Jenn Bennett Courtney L. Biolocity Paul Grewal Fatima Cody Stanford

Metric
Company Name	Pier 70 Ventures
Symbol
MSH ID	COM:PIER70VENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	US
Stage
Employee Count	14
Website	pier70ventures.com
LinkedIn	pier-70-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	79
Web Traffic Growth	-0.96
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PIER70VENTURES

Pier 70 Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue